Suggested remit - To appraise the clinical and cost effectiveness of fostamatinib within its marketing authorisation for treating persistent or chronic immune thrombocytopenia.
Status In progress
Process STA 2018
ID number 1087

Provisional Schedule

Committee meeting: 2 05 May 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors Grifols (fostamatinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Royal College of Pathologists
  UK ITP Forum


Comparator companies Sanofi (danazol)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency National Association
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research


Key events during the development of the guidance:

Date Update
11 November 2020 - 02 December 2020 Appraisal consultation
14 October 2020 Committee meeting: 1
26 June 2020 Fostamatinib for treating persistent or chronic immune thrombocytopenia was due to pause , however the topic will now continue on the original timelines and will no longer pause. The timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly
02 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
14 February 2020 Invitation to participate
14 February 2020 In progress. In progress
06 August 2019 - 04 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
22 October 2018 The company that is developing fostamatinib have shared confidential information with NICE. As a result the Institute will not be progressing with the scoping exercise at this current time. Consequently the consultation on the draft scope will now be closed early. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance